CHMP gives go-ahead to ProStrakan's Sancuso
This article was originally published in Scrip
The European Medicines Agency's scientific committee, the CHMP, has adopted a positive opinion for ProStrakan's Sancuso (granisteron) transdermal patch, recommending that the EMA grants marketing authorisation for the product. ProStrakan was acquired last year by Kyowa Hakko Kirin.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.